About Lindy Biosciences
Lindy Biosciences is a Healthcare company based in Durham (United States) founded in 2016. It operates as a formulation technology for bio-therapeutics drug delivery is developed. Lindy Biosciences has raised $7.26 million across 5 funding rounds from investors including Good Growth Capital, IAG Capital Partners and Fulcrum Financial Partners. The company has 4 employees. Lindy Biosciences offers products and services including Microglassification Technology. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Formulation. Its legal entity is Lindy Biosciences, Inc. Its competitors include Elektrofi, Archon Bio, NovaLead Pharma, Etcembly and SQALE and 1 more; 4 of its 6 listed competitors have raised funding.
Company details
Lindy Biosciences was founded in 2016 in Durham, United States, within the biotechnology sector. Formulation technology for bio-therapeutics drug delivery is focused on by the company. Spherical, dense, stable particles of therapeutic proteins are produced to enable non-standard applications, including suspension formulations for high-concentration antibody delivery, encapsulation for sustained or controlled release, and dry powder pulmonary delivery. Operations center on advancing these particle-based solutions for improved drug administration.
- Headquarters Durham, United States
- Employees 4
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lindybio.com
- Social LinkedIn
- Legal Name Lindy Biosciences, Inc.
- Total Equity Funding$7.26M (USD)
in 5 rounds
- Latest Funding Round$1.71M (USD), Series B
Mar 2024
- InvestorsGood Growth Capital
& 2 more
- Employee Count4
Products & Services of Lindy Biosciences
Lindy Biosciences offers a comprehensive portfolio of products and services, including Microglassification Technology.
Enables self-administration of biotherapeutic drugs at home.
Funding Insights of Lindy Biosciences
Lindy Biosciences has successfully raised a total of $7.26M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $1.71 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.26M
- Total Rounds 5
- Last Round Series B — $1.71M
- First Round $150,000
(Mar 2018)
- Investors Count 3
All 5 funding rounds of Lindy Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $1.71M | Series B | – | – | – |
| Mar 2022 | $3.25M | Series B | – | IAG Capital Partners | |
| Jun 2020 | $1.6M | Series A | – | – | – |
| Jan 2019 | $547,736 | Seed | – | – | – |
| Mar 2018 | $150,000 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in Lindy Biosciences
Lindy Biosciences has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Good Growth Capital, IAG Capital Partners and Fulcrum Financial Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are provided by IAG Capital Partners. | – | iagcapitalpartners.com | Charleston, USA | |
Early-stage investments are made in life sciences and technologies. | 2017 | goodgrowthvc.com | Charleston, United States | |
Financial investments are provided to local startups by Fulcrum. | 2007 | fulcrumfs.com | Raleigh, United States |
Investor details for Lindy Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lindy Biosciences
6 people are tracked at Lindy Biosciences (2 in leadership, 4 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Deborah Bitterfield | CEO & Founder | Leadership |
John Savage | Senior Director, Technical Operations | Leadership |
Adam Ryle | Engineer | Team |
Tia Young | Principal Scientist | Team |
Karthik Balakrishna Chandrababu | Senior Analytical Scientist | Team |
Alex Tate | Scientist I | Team |
Complete people profiles for Lindy Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Lindy Biosciences
3 dated milestones of Lindy Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Lindy Biosciences is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Series B, of $1.7M.
Competitors of Lindy Biosciences
Lindy Biosciences has 6 listed competitors in our database, 4 of them funded. They include Elektrofi, Archon Bio, NovaLead Pharma, Etcembly and SQALE, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| archon.bio | 2023 | Seattle, United States | $20M | – | Provider of computational platform to develop protein therapeutics | |
| novaleadpharma.com | 2007 | Pune, India | $8.04M | – | Drug repurposing and discovery are enabled by a proprietary platform. | |
| etcembly.io | 2020 | Harwell, United Kingdom | $12.66M | – | Provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy | |
| sqale.ai | 2023 | Copenhagen, Denmark | – | – | Provides bioprocess optimization services for microalgae and precision fermentation companies. | |
| neuromathix.com | 2001 | Brisbane, Australia | – | – | Offers decision support software for personalized healthcare models based on patient data. |
Detailed competitors of Lindy Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lindy Biosciences
The website of Lindy Biosciences (lindybio.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▼ 51.5% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Lindy Biosciences (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lindy Biosciences
Complete news archive for Lindy Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lindy Biosciences
Lindy Biosciences was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Lindy Biosciences is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Lindy Biosciences is a funded company, having raised a total of $7.26M across 5 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Mar 2018.
Lindy Biosciences has 4 employees.
Lindy Biosciences was founded in 2016 in Durham, United States, within the biotechnology sector. Formulation technology for bio-therapeutics drug delivery is focused on by the company. Spherical, dense, stable particles of therapeutic proteins are produced to enable non-standard applications, including suspension formulations for high-concentration antibody delivery, encapsulation for sustained or controlled release, and dry powder pulmonary delivery. Operations center on advancing these particle-based solutions for improved drug administration.
Lindy Biosciences's top competitors include Elektrofi, Etcembly and Archon Bio.
Lindy Biosciences offers Microglassification Technology.
Lindy Biosciences has 3 investors. Key investors include Good Growth Capital, IAG Capital Partners, and Fulcrum Financial Partners.
Lindy Biosciences operates through Lindy Biosciences, Inc..